RxDoctor Payments Data

Pamela Voelker, MD

Ophthalmology · St Louis Park, MNNPI 1134312416

Payments from drug & device makers

$519in general payments, 2019–2025

Across 12 payments — averaging $43.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$107
  • Dompe US, Inc.$104
  • Carl Zeiss Meditec, Inc.$101
  • Alcon$94
  • The Cameron-ehlen Group, Inc.$88
  • Novartis$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Glaukos Corporation2$107
Dompe US, Inc.1$104
Carl Zeiss Meditec, Inc.2$101
Alcon4$94
The Cameron-ehlen Group, Inc.1$88
Novartis1$14
Oyster Point Pharma, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$519 in reported general payments places this provider in the 60th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$116,533
Medicare patients
258
Services billed
962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost88$46,960
XiidraLifitegrast20$25,425
RestasisCyclosporine33$25,285
RhopressaNetarsudil Mesylate33$14,828
Brimonidine Tartrate94$13,714
RocklatanNetarsudil Mesylat/Latanoprost13$13,395
Prednisolone Acetate419$13,270
TyrvayaVarenicline Tartrate11$12,688
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$11,498
Travoprost56$11,450
Alphagan PBrimonidine Tartrate20$9,432
VyzultaLatanoprostene Bunod24$8,188
Latanoprost402$6,752
Fluorometholone95$6,075
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat236$4,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$12$12,68811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in St Louis Park

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →